Segment reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table presents the significant revenue and expense categories in the Company’s single operating and reporting segment:

	Year ended December 31,
(in thousands)	2024		2023		2022
Collaboration revenue	$	40,497	$	36,855	$	26,581
Research and development expense:
Emi-Le external costs	17,642		14,098		15,032
XMT-2056 external costs	6,396		5,812		4,981
UpRi external costs	379		48,902		66,119
XMT-1592 external costs	—		434		3,802
Preclinical and discovery external costs (a)	(625)		4,441		14,991
Internal research and development expense (b)	40,339		63,539		57,074
General and administrative expense	33,244		49,450		46,827
Stock-based compensation expense	16,458		21,136		21,522
Restructuring expense	—		8,713		—
Other:
Interest income	8,436		12,073		2,883
Interest expense	(3,874)		(4,073)		(3,328)
Income tax expense	(418)		0		0
Segment and consolidated net loss	$	(69,192)	$	(171,670)	$	(204,212)

(a) The amount for the year ended December 31, 2024 primarily reflect the favorable resolution of an accrual balance.

(b) Internal research and development expenses primarily consist of research and development employee compensation, allocated facility-based expenses and other indirect costs.